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Abstract
Background: The purpose of this study was to assess the association between new onset of
atrial fibrillation (AF) and in-hospital management and mortality in acute coronary syn-
drome patients admitted to hospitals without on-site invasive facilities.
Methods: We assessed data concerning in-hospital management and mortality of 24 patients
with, and 977 patients without, new onset of AF from the Krakow Registry of Acute Coronary
Syndromes database.
Results: Patients with new onset of AF were older and more likely to have diabetes, chronic
obstructive pulmonary disease, cardiogenic shock and chest pain on admission, and a shorter
time from the onset of symptoms to admission. These patients more frequently received glyco-
protein IIb/IIIa inhibitors, thrombolytics, and were less likely to be treated with statins during
their hospital stay. Risk of AF occurrence was lower in patients treated with statins (1.9% vs
5.2%; p = 0.021). Among patients treated conservatively, in-hospital mortality was higher in
patients with new onset of AF (8.1% vs 33.3%; p = 0.001). Independent predictors of in-
hospital death in this group of patients were: new onset of AF, age, cardiogenic shock, chronic
obstructive pulmonary disease, history of renal insufficiency, and discharge diagnosis.
Conclusions: New onset of AF is associated with excessive in-hospital mortality in acute
coronary syndrome patients staying on conservative treatment in community hospitals without
on-site invasive facilities. (Cardiol J 2010; 17, 1: 57–64)
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Introduction
Atrial fibrillation (AF) is a very common su-
praventricular arrhythmia which complicates the
course of acute coronary syndrome (ACS). Previ-
ous studies have shown that new onset of AF is
associated with increased short- and long-term
mortality in patients presenting either with or with-
out ST-segment elevation ACS [1–12]. Other stud-
ies however have not shown this [12–14]. On the oth-
er hand, in most previous studies there has been very
little usage of guideline-recommended therapies, es-
pecially statins, which have been shown to be as-
sociated with a decreased risk of AF onset [15, 16].
The purpose of our study was to assess the
association between new onset of AF and in-hospi-
tal outcomes in patients with ACS admitted to hos-
pitals without on-site invasive facilities.
Methods
The Krakow Registry of Acute Coronary Syn-
dromes was a prospective, multi-center, observa-
tional registry designed to examine current epide-
miology, in-hospital management and outcome of
patients with ACS in this region of Poland (Krakow,
Malopolska Region). The design and main results of
the Registry have been described previously [17, 18].
Cardiogenic shock was defined as reduced blood
pressure (systolic blood pressure < 90 mm Hg
or a drop of mean arterial pressure > 30 mm Hg)
and/or low urine output (< 0.5 mL/kg/h), with
a pulse rate > 60 beats per minute with or without
evidence of organ congestion [19]. Patients were
classified as non-ST-segment elevation myocardial
infarction (NSTEMI) and ST-segment elevation
myocardial infarction (STEMI) based on their final
diagnosis. STEMI was diagnosed if ST-segment
elevation ≥ 1 mm occurred in ≥ 1 lead or new left
bundle branch block was found in electrocardiogram
with biochemical evidence of myocardial necrosis
(≥ 1 positive biochemical cardiac necrosis markers
measurement). NSTEMI was diagnosed in patients
with ≥ 1 positive biochemical cardiac necrosis
markers measurement without new ST-segment el-
evation in electrocardiogram. The primary end point
was in-hospital mortality. New onset of AF was
defined as new AF that occurred during hospital
stay in patients presenting with sinus rhythm on ad-
mission. It was diagnosed by local physicians.
The study was approved by the local bioethi-
cal committee.
Statistical analysis
Data was analyzed according to the established
standards of descriptive statistics. Values were
expressed as mean ± standard deviation. Categor-
ical variables were presented as percentages. Sta-
tistical comparisons between groups were per-
formed using c2 test and Fisher’s exact test for cat-
egorical variables and Mann-Whitney U test for
continuous variables, as appropriate. Logistic re-
gression analysis was performed to find independ-
ent predictors of new onset of AF occurrence. In
the first model, the following covariates were test-
ed: gender, age, body mass index, presence of dia-
betes mellitus, arterial hypertension, hyperlipidae-
mia, prior angina, prior myocardial infarction, prior
heart failure symptoms, left ventricular ejection
fraction, prior percutaneous coronary intervention,
prior coronary artery bypass graft, prior stroke/
/transient ischemic attack, history of smoking, pe-
ripheral arterial disease, chronic renal insufficien-
cy, chronic obstructive pulmonary disease, pa-
rameters on admission (chest pain presence, car-
diogenic shock presence, heart rate, systolic
blood pressure, diastolic blood pressure), time
from chest pain onset to admission, and discharge
diagnosis.
In the second model, usages of each pharma-
cological agent during hospital stay were tested as
covariates. The third model was a combination of
the previous two models. Results were presented
as odds ratios with 95% confidence intervals. Oc-
currence of primary end point was assessed in pre-
specified groups (cardiogenic shock vs. no cardio-
genic shock presence, final diagnosis of STEMI vs
NSTEMI vs unstable angina) and the Breslow-Day
test for homogeneity was used to prove possible
interactions. In addition, multivariate Cox regres-
sion analysis was performed to find significant pre-
dictors of in-hospital death. The same covariates as
used in logistic regression analysis model number
1 were tested and forward selection in Cox regres-
sion with the probability value for covariates to
enter the model set at 0.05 level. Risk of in-hospi-
tal death was expressed as hazard ratio with 95%
confidence interval. All tests were two-tailed, and
a p value of < 0.05 was considered statistically sig-
nificant.
Results
The Krakow Registry of Acute Coronary Syn-
dromes database included 1,414 patients with sus-
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pected ACS admitted between February 2005 and
March 2005, and between December 2005 and Jan-
uary 2006. A total of 101 patients with a final diag-
nosis other than ACS (stable angina or extracardi-
ac cause of chest pain) were excluded from the anal-
ysis. Of the remaining 1,313 patients, 312 (23.8%)
were transferred for invasive treatment. The oth-
er 1,001 (76.2%) patients were treated conserva-
tively during hospital stay: this was the studied
group, as set out in Figure 1. A total of 44 (4.4%)
patients were in cardiogenic shock on admission.
At discharge, 194 (19.4%) patients had a final diagno-
sis of STEMI, 289 (28.9%) a diagnosis of NSTEMI,
and 517 (51.7%) a diagnosis of unstable angina. New
onset of AF was diagnosed in 24 (2.4%) patients.
The observed frequency was similar among patients
with discharge diagnosis of STEMI, NSTEMI, and
unstable angina (3.1% vs. 2.8% vs. 1.9% respective-
ly; p = 0.53). It was observed more frequently in
shock than in non-shock patients (16.7% vs. 4.1%;
p = 0.018).
Baseline demographic and clinical characteris-
tics of patients with and without new onset of AF
are summarized in Table 1. Patients with new on-
set of AF were older and were more likely to have
diabetes mellitus, chronic obstructive pulmonary
disease, chest pain on admission, and a shorter time
from the onset of symptoms to admission. Patients
with new onset of AF were more likely to be in car-
diogenic shock, with higher heart rate and lower
systolic blood pressure on admission. Importantly,
there was no difference in discharge diagnosis be-
tween study groups. Diabetes mellitus and pres-
ence of chest pain on admission, as well as heart
rate and systolic blood pressure on admission, were
independent predictors of new onset of AF (Table 2,
model 1).
As shown in Table 3, patients with new onset
of AF were more likely to receive glycoprotein IIb/
/IIIa inhibitors, thrombolytics, and less likely to be
treated with statins during hospital stay. Trends
toward less frequent use of aspirin and more fre-
quent use of low-molecular-weight heparin in pa-
tients with new onset of AF were also observed.
Patients treated with statins were at lower risk of AF
than untreated patients (1.9% vs. 5.2%; p = 0.021).
Use of glycoprotein IIb/IIIa inhibitors, thromboly-
tics, low-molecular-weight heparin, and statins were
independently associated with new onset of AF
(Table 2, model 2), but this association was no longer
significant after adjustment for clinical covariates
(Table 2, model 3).
Among patients treated conservatively during
hospital stay, the highest in-hospital mortality was
Figure 1. Scheme of groups distribution in the registry; AF — atrial fibrillation.
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observed among patients with discharge diagnosis
of STEMI (STEMI vs NSTEMI vs unstable angina,
22.7% vs 12.1% vs 1.5% respectively; p < 0.0001).
Also mortality was higher in shock than in non-
shock patients (shock vs non-shock, 63.6% vs
6.2%; p < 0.0001). In-hospital mortality was high-
er in patients with new onset of AF [AF (–) vs AF
(+), 8.1% vs 33.3%; p = 0.001]. In-hospital mor-
tality rates for patients with and without new onset
of AF, stratified by cardiogenic shock presence on
admission and discharge diagnosis, are shown in
Figure 2. Tests for interaction and multivariate Cox
regression analysis (Table 4) have confirmed that
new onset of AF was independently associated with
excess of in-hospital mortality in patients with ACS
treated conservatively during hospital stay. Influ-
ence of new onset of AF on in-hospital mortality was
especially expressed in lower risk individuals (non-
shock, unstable angina). In patients with new on-
set of AF, a trend toward higher risk of ischemic
stroke [AF (–) vs AF (+), 0.6% vs 4.2%; p = 0.16],
but not hemorrhagic stroke (0.1% vs 0.0%; p = 0.99)
occurrence during hospital stay was observed.
There was no difference in blood transfusion rate
between groups (1.5% vs 0.0%; p = 0.99). Among
survivors, mean hospital stay was significantly
shorter in patients without AF (9.1 ± 5.0 vs 12.4 ±
± 6.1 days; p = 0.008).
Table 1. Baseline demographic and clinical characteristics.
Characteristics New onset of AF OR (95% CI) P
No (n = 977) Yes (n = 24)
Male 54.0 50.0 0.85 (0.38–1.91) 0.84
Age (years) 69.0±11.7 74.8±8.6 – 0.014
Age >75 years 31.8 50.0 2.14 (0.95–4.82) 0.08
Body mass index [kg/m2] 27.3±6.0 27.0±2.9 – 0.71
Diabetes mellitus 22.8 45.8 2.86 (1.26–6.48) 0.014
Arterial hypertension 78.9 79.2 1.02 (0.38–2.75) 0.99
Hyperlipidemia 57.8 45.8 0.62 (0.27–1.39) 0.30
Prior angina 71.3 75.0 1.21 (0.47–3.07) 0.82
Prior myocardial infarction 33.2 29.2 0.83 (0.34–2.02) 0.83
Prior heart failure symptoms 23.7 29.2 1.32 (0.54–3.23) 0.63
Prior PCI 7.8 0.0 – 0.25
Prior CABG 4.3 0.0 – 0.62
Prior stroke/TIA 6.0 4.2 0.68 (0.09–5.10) 0.99
Current smoker 26.7 33.3 1.37 (0.58–3.24) 0.49
Family history of CAD 13.2 12.5 0.94 (0.28–3.19) 0.99
COPD 10.6 29.2 3.46 (1.40–8.53) 0.012
Peripheral arterial disease 11.9 4.2 0.32 (0.04–2.41) 0.35
History of renal insufficiency 6.1 0.0 – 0.39
Chest pain on admission 59.4 91.7 7.53 (1.76–32.20) 0.001
Time from chest pain onset to admission [h] 17.6±21.4 12.0±18.2 – 0.048
Time from chest pain onset to admission £ 12 h 37.9 29.2 0.67 (0.28–1.64) 0.41
Heart rate on admission [beat/min] 83.7±23.0 104.7±36.7 – 0.002
SBP on admission [mmHg] 145.0±31.9 125.5±40.9 – 0.004
DBP on admission [mm Hg] 86.8±15.1 81.7±16.0 – 0.27
Cardiogenic shock on admission 4.1 16.7 4.69 (1.53–14.35) 0.018
LVEF (%) 53.4±13.2 51.0±10.4 – 0.20
Discharge diagnosis:
STEMI 19.2 25.0
NSTEMI 28.8 33.3 – 0.53
Unstable angina 52.0 41.7
Values are presented as percentages or mean ± standard deviation; AF — atrial fibrillation; CABG — coronary artery bypass grafting; CAD — coronary
artery disease; CI — confidence interval; COPD — chronic obstructive pulmonary disease; DBP — diastolic blood pressure; LVEF — left ventricular
ejection fraction; NSTEMI — non-ST-segment elevation myocardial infarction; OR — odds ratio; PCI — percutaneous coronary intervention;
SBP — systolic blood pressure; STEMI — ST-segment elevation myocardial infarction; TIA — transient ischemic attack
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Discussion
Our study is the first to show the prognostic
influence of new onset AF on outcomes of a specif-
ic subgroup of ACS patients: patients treated con-
servatively during hospital stay. Regardless of the
risk profile (age, discharge diagnosis, and presence
of cardiogenic shock, chronic obstructive pulmonary
disease, history of renal insufficiency) new onset AF
has been shown to be an independent predictor of
in-hospital death.
Observed frequency of AF was the one of the
lowest ever reported in an ACS setting [1–15]. Sev-
eral explanations can be suggested. In many previ-
ous studies, the impact of AF was assessed com-
bining patients with pre-existing or new AF [1, 4, 14],
not just new onset AF patients [2, 3, 5–9, 13].
Most studies were limited to acute myocardial
Table 2. Logistic regression analysis for new onset of atrial fibrillation occurrence.
Variable OR 95% CI P
Model 1
Diabetes mellitus 4.07 1.53–10.88 0.005
Chest pain on admission 7.11 1.59–31.91 0.010
Heart rate on admission (per 1 beat/min) 1.02 1.00–1.04 0.012
Systolic blood pressure on admission (per 1 mm Hg) 0.98 0.96–1.00 0.020
Model 2
Glycoprotein IIb/IIIa inhibitor 4.00 1.00–16.08 0.050
Thrombolysis 5.53 1.37–22.27 0.016
Low-molecular-weight heparin 5.76 1.28–25.92 0.023
Statins 0.28 0.11–0.68 0.005
Model 3
Diabetes mellitus 2.53 1.04–6.11 0.040
Chest pain on admission 7.62 1.71–33.85 0.008
Chronic obstructive pulmonary disease 3.22 1.22–8.51 0.019
Heart rate on admission (per 1 beat/min) 1.02 1.01–1.04 0.002
Systolic blood pressure on admission (per 1 mm Hg) 0.98 0.97–1.00 0.041
Thrombolysis 3.65 0.93–14.32 0.063
CI — confidence interval; OR — odds ratio
Table 3. Pharmacological treatment during hospital stay.
Characteristics New onset of AF OR (95% CI) P
No (n = 977) Yes (n = 24)
Aspirin 95.3 87.5 0.35 (0.10–1.20) 0.11
Clopidogrel 9.3 4.2 0.42 (0.06–3.17) 0.72
Ticlopidine 18.6 20.8 1.15 (0.42–3.12) 0.79
Glycoprotein IIb/IIIa inhibitor 3.0 12.5 4.67 (1.32–16.54) 0.038
Thrombolysis 2.6 12.5 5.44 (1.52–19.43) 0.027
Low-molecular-weight heparin 73.3 91.7 4.01 (0.94–17.17) 0.06
Beta-blocker 81.0 70.8 0.57 (0.23–1.40) 0.20
ACEI/angiotensin II antagonist 75.9 58.3 0.44 (0.19–1.01) 0.06
Calcium antagonist 11.2 0.0 – 0.10
Nitrates 69.7 66.7 0.87 (0.37–2.05) 0.82
Statins 85.1 66.7 0.35 (0.15–0.84) 0.02
Values are presented as percentages; ACEI — angiotensin-converting enzyme inhibitor; AF — atrial fibrillation; CI — confidence interval; OR — odds ratio
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infarction patients, especially STEMI patients [2–7,
13, 14]. In our study, associations between AF and
outcomes were assessed in a broad spectrum of
unselected ACS patients, including unstable angi-
na patients with a potentially lower risk of new on-
set AF occurrence. Also, a significant decline in the
incidence of AF complicating acute myocardial in-
farction has been recently reported [13, 14]. It may
be associated with higher adherence to guideline-
recommended therapies, especially a higher use of
statins. Statins were used in almost of 85% of pa-
tients and in line with previous reports their use
was associated with a decreased risk of AF occur-
rence [15, 16].
New onset of AF has been associated with ad-
vanced age [1–13, 15], diabetes mellitus [2, 4, 6, 7,
10, 15], chronic obstructive pulmonary disease [4],
higher heart rate [1, 2, 5, 8–10] and lower systolic
blood pressure on admission [5, 7, 8] and presence
of cardiogenic shock on admission [1, 7]. Previous
studies have also reported a higher prevalence of
new onset AF in patients with congestive heart fail-
ure [4, 6–8], poor left ventricular function [10, 20],
presence of mitral insufficiency [20], prior myocar-
dial infarction [1, 7] and without previous coronary
artery bypass grafting [1, 5, 8, 9]. Higher rates of
new onset AF in patients treated with thrombolyt-
ics and glycoprotein IIb/IIIa inhibitors may be driv-
en rather by differences in the discharge diagnosis
and risk profile (these drugs were used in STEMI
patients only) than by any direct association be-
tween the drugs and AF occurrence.
New onset of AF was associated with a more
than doubling in in-hospital mortality in patients
with ACS treated conservatively. There are many
potential mechanisms responsible for poor short-
and long-term prognosis in patients with ACS and
new onset of AF. It is still debatable whether AF
itself poses a risk for patients with ACS, or is merely
a benign marker of disease severity [11, 12]. New
onset of AF is frequently associated with conges-
tive heart failure, advanced age and higher preva-
lence of age-related diseases (e.g. renal insufficien-
cy, diabetes mellitus, chronic obstructive pulmo-
Figure 2. In-hospital mortality in patients without (empty bars) and with (solid bars) new onset of atrial fibrillation
stratified by cardiogenic shock presence on admission and discharge diagnosis; AF — new onset of atrial fibrillation;
NSTEMI — non-ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial infarction.
Table 4. Multivariate Cox regression analysis for in-hospital death.
Variable Hazard ratio 95% CI P
STEMI (vs unstable angina) 6.98 3.19–15.25 < 0.001
NSTEMI (vs unstable angina) 3.91 1.78–8.56 0.001
Cardiogenic shock 5.34 3.25–8.77 < 0.001
New onset of atrial fibrillation 2.66 1.26–5.62 0.010
Chronic obstructive pulmonary disease 1.97 1.20–3.25 0.008
History of renal insufficiency 1.77 1.00–3.13 0.050
Age (per 1 year) 1.02 1.00–1.04 0.040
CI — confidence interval; NSTEMI — non-ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial infarction
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nary disease, stroke), which were themselves
shown to be associated with adverse outcomes in
ACS patients [21–25]. On the other hand, AF may
cause rapid hemodynamic instability through loss
of the atrial component of the cardiac output, in-
creased ventricular response rate with decreased
diastolic filling time, and irregular ventricular filling
[26, 27]. Also, a recent study by Berton et al. [10]
confirmed that patients with AF occurrence in an
acute myocardial infarction setting were at higher
risk of sudden death and chronic heart failure re-
lated death during seven-year follow-up.
Similarly to the GRACE Registry data, STEMI
diagnosis was associated independently with worse
in-hospital prognosis than NSTEMI and unstable
angina [28]. The second independent predictor
of in-hospital death in the analyzed patient popula-
tion was cardiogenic shock (more than fivefold in-
creased risk of in-hospital death). Interestingly,
increase in in-hospital mortality associated with
new onset of AF was expressed rather in lower risk
individuals, non-shock and unstable angina patients.
In line with previous papers, chronic obstructive
pulmonary disease [23], renal insufficiency [21, 22],
and age [29, 30] were independent predictors of an
unfavorable outcome in ACS patients.
New AF may be associated not only with high-
er mortality, but also with other complications dur-
ing short- and long-term follow-up [1, 2, 4, 5, 7, 8,
10, 12, 13]. In our study, a trend toward higher risk
of ischemic stroke during hospital stay was ob-
served in patients with new onset of AF. This has
also been reported in previous studies [1, 5, 7, 8, 13].
Importantly, this increased risk of stroke may per-
sist during long-term follow-up [1, 11–13]. Patients
with AF are also at higher risk of ventricular fibri-
llation/ventricular tachycardia [2–4, 7, 8], condu-
ction disturbances [3, 7], reinfarction [1, 2, 5, 7, 8],
congestive heart failure [2, 4, 5, 7], and bleeding
events [1, 8]. These complications may lead to pro-
longation of hospital stay [5, 8].
Limitations of the study
Several important limitations of the present
study deserve discussion. First, the study has all
the limitations of a registry. Secondly, a relatively
small group size is also a limitation. The study fo-
cused only on in-hospital clinical outcomes of pa-
tients treated conservatively in centers without on-
site invasive facilities. Data concerning mortality in
the group of patients transferred for invasive treat-
ment, as well as long-term clinical follow-up data
for all patients, was not available. Additionally, new
onset of AF was diagnosed based on local physician
assessment. Data concerning treatment used for
AF, as well as timing, duration, and final outcome
of AF was not assessed. However, observed asso-
ciations between new onset of AF and in-hospital
mortality are in line with previous reports and are
clinically important.
Conclusions
New onset atrial fibrillation is associated with
excessive in-hospital mortality in ACS patients
remaining in community hospitals without on-site
invasive facilities for conservative treatment.
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